PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ), an emerging specialty pharmaceutical company, today announced that clinical data highlighting the safety profile of EXPAREL™ (bupivacaine extended-release liposome injection) will be presented at the 2011 International Anesthesia Research Society (IARS) Annual Meeting in Vancouver, British Columbia.
Comprehensive, program-wide safety data for EXPAREL will be presented by Dr. Eugene R. Viscusi, Director, Acute Pain Management, Department of Anesthesiology, Jefferson Medical College, Thomas Jefferson University, on Monday, May 23, 2011 at 2:45 p.m. ET. Dr. Viscusi's presentation, titled "The Safety of EXPAREL™, A Multivesicular Liposomal Extended-Release Bupivacaine" examines the safety profile of EXPAREL in 823 patients across ten wound infiltration studies and five surgical procedures, including hemorrhoidectomy, bunionectomy, total knee arthroplasty, breast augmentation and hernia repair.
Pacira also announced that comprehensive, program-wide efficacy data for EXPAREL was highlighted at IARS. Dr. Sergio Bergese, associate professor of anesthesiology and neurological surgery, The Ohio State University, presented the poster, titled, "The Efficacy of EXPAREL™, A Multivesicular Liposomal Extended-Release Bupivacaine" on Sunday, May 22, 2011 at 8 a.m. ET. The poster was previously presented May 11, 2011 at the Society for Ambulatory Anesthesia (SAMBA) 26th Annual Meeting in San Antonio; this is the first time that the program wide efficacy and safety data have been presented together.
"We are excited to present these data, which support the utility of EXPAREL across multiple surgical models," said David Stack, president and chief executive officer of Pacira Pharmaceuticals. "While EXPAREL was well-tolerated across all doses, based upon clinical experience